Asset Details
Do you wish to reserve the book?
P7 Native liver survival in odevixibat serum bile acid responders: Data from PEDFIC studies in patients with progressive familial intrahepatic cholestasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P7 Native liver survival in odevixibat serum bile acid responders: Data from PEDFIC studies in patients with progressive familial intrahepatic cholestasis
Do you wish to request the book?
P7 Native liver survival in odevixibat serum bile acid responders: Data from PEDFIC studies in patients with progressive familial intrahepatic cholestasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P7 Native liver survival in odevixibat serum bile acid responders: Data from PEDFIC studies in patients with progressive familial intrahepatic cholestasis
2023
Overview
IntroductionPatients with progressive familial intrahepatic cholestasis (PFIC) may have continued hepatic damage leading to liver transplantation (LT). Efficacy and safety of odevixibat, an ileal bile acid transporter inhibitor, were assessed in patients with PFIC in the phase 3 PEDFIC 1 and PEDFIC 2 studies. In a pooled analysis of data from these studies, we analysed native liver survival (NLS) in odevixibat-treated patients who met serum bile acid (sBA) treatment response criteria (sBAs reduced ≥70% or levels ≤70 µmol/L at 6 months). NLS was also analysed in partial sBA responders (patients with sBA reductions ≥30% to <70% at 6 months) and nonresponders (patients with sBA reductions <30% at 6 months or who underwent LT or discontinued treatment before 6 months).MethodsPEDFIC 1 was a 24-week, randomised, placebo-controlled study in children with PFIC1 or PFIC2. PEDFIC 2 is an ongoing 72-week extension study in patients of any age with any PFIC type. This pooled analysis spans from patients’ first dose of odevixibat to a cut-off date of 31 January 2022.ResultsOf 98 patients analysed (mean treatment duration, 88 weeks), 35 (36%) were sBA responders, 14 (14%) were partial sBA responders, and 49 (50%) were nonresponders. Mean sBA reductions at 6 months were 87% in responders and 44% in partial responders; there was a mean increase of 27% in nonresponders. All 35 sBA responders and 13 of the 14 partial sBA responders remained transplant free; 8 of the 49 nonresponders underwent LT (figure 1). sBA responders had mean improvements at week 24 of treatment vs baseline in alanine aminotransferase and total bilirubin levels.Conclusions sBA decreases at 6 months were strongly associated with NLS for up to 3 years in odevixibat-treated patients with PFIC.Abstract P7 Figure 1Native liver survival in serum bile acid responders, partial responders, and nonresponders to odevixibat in the PEDFIC studies[Figure omitted. See PDF]
Publisher
BMJ Publishing Group LTD
Subject
